The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Open accessAbstract
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“Approximately 60% of basal TNBCs bear mutations in p53 (15) and ~90% of mutations in p53 occur in the DNA binding domain.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
Cited by
Sorted by citations
Items 901–1,000 of 1,003
Kim, Y., Lee, H. J., Heo, S., Park, H. S., Park, S. Y., Bang, W. S., Song, I. H., Park, I. A., & Gong, G. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3786-z · Cited by 28
Goswami, I., Coutermarsh‐Ott, S. L., Morrison, R. G., Allen, I. C., Davalos, R. V., Verbridge, S. S., & Bickford, L. R. (2016) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2016.09.003 · Cited by 28
Balanis, N. G., & Carlin, C. R. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.013 · Cited by 28
The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer
Guo, Y. P., Yu, H., Wang, J., Sheng, Q., Zhao, S., Zhao, Y., & Lehmann, B. D. (2018) · Genes · doi:10.3390/genes9010029 · Cited by 28
Self-citationWu, N., Zhang, J., Zhao, J., Mu, K., Zhang, J., Jin, Z., Yu, J., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9290 · Cited by 30
Sprouffske, K., Kerr, G., Li, C., Prahallad, A., Rebmann, R., Waehle, V., Naumann, U., Bitter, H., Jensen, M. R., Hofmann, F., et al. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.01.008 · Cited by 29
An Integrated Human Mammary Epithelial Cell Culture System for Studying Carcinogenesis and Aging
Stampfer, M. R., LaBarge, M. A., & Garbe, J. C. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-634-4_15 · Cited by 29
Vidula, N., & Bardia, A. (2017) · Oncotarget · doi:10.18632/oncotarget.22580 · Cited by 29
Burleigh, A., McKinney, S. E., Brimhall, J., Yap, D., Eirew, P. D., Poon, S. S. S., Ng, V., Wan, A. N. C., Prentice, L., Annab, L. A., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-014-0510-y · Cited by 28
Self-citationChoudhary, A., Mambo, E., Sanford, T., Boedigheimer, M. J., Twomey, B., Califano, J. A., Hadd, A. G., Oliner, K. S., Beaudenon, S. L., Latham, G. J., et al. (2014) · BMC Medical Genomics · doi:10.1186/s12920-014-0062-0 · Cited by 27
Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer
Han, H. S., & Magliocco, A. M. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.02.016 · Cited by 27
Han, C., Liao, X., Qin, W., Yu, L., Liu, X., Chen, G., Liu, Z., Lu, S., Chen, Z., Su, H., et al. (2016) · Scientific Reports · doi:10.1038/srep31237 · Cited by 27
Park, I. H., Kong, S., Kwon, Y., Kim, M. K., Sim, S. H., Joo, J., & Lee, K. S. (2018) · Journal of Cancer · doi:10.7150/jca.24035 · Cited by 27
Luo, Z.-H., Fan, X., Yao, S., & Huang, Y. S. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty043 · Cited by 27
DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid
Coyle, K. M., Dean, C. A., Thomas, M. L., Vidovic, D., Giacomantonio, C. A., Helyer, L. K., & Marcato, P. (2018) · Cancers · doi:10.3390/cancers10110397 · Cited by 27
Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling
Scherer, F. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_11 · Cited by 26
Lin, L., Li, Y., Han, H., & Lin, S. (2021) · Aging · doi:10.18632/aging.202363 · Cited by 27
Li, K., Zhang, T., Zhao, C., Wang, F., Cui, B., Yang, Z.-N., Lv, X., Yeerjiang, Z., Yuan, Y., Yu, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2914 · Cited by 27
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey, N., Aske, J. C., & Pradip, D. (2021) · Pharmaceuticals · doi:10.3390/ph14050455 · Cited by 26
New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
Hejjioui, B. E., Lamrabet, S., Joutei, S. A., Senhaji, N., Bouhafa, T., Malhouf, M. A., Bennis, S., & Bouguenouch, L. (2023) · Diagnostics · doi:10.3390/diagnostics13111949 · Cited by 28
Small molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 27
Downing, T. (2015) · Microorganisms · doi:10.3390/microorganisms3020236 · Cited by 26
Kenicer, J., Spears, M., Lyttle, N., Taylor, K. J., Liao, L., Cunningham, C., Lambros, M. B. K., Mackay, A. G., Yao, C. Q., Reis-Filho, J. S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-762 · Cited by 27
Personal genomes, quantitative dynamic omics and personalized medicine
Mias, G. I., & Snyder, M. P. (2013) · Quantitative Biology · doi:10.1007/s40484-013-0005-3 · Cited by 29
Coradini, D., Biganzoli, E. M., Ardoino, I., Ambrogi, F., Boracchi, P., Demicheli, R., Daidone, M. G., & Moliterni, A. (2015) · The Breast · doi:10.1016/j.breast.2015.01.007 · Cited by 27
Cancer heterogeneity and “The Struggle for Existence”: Diagnostic and analytical challenges
Horswell, S. D., Matthews, N., & Swanton, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.031 · Cited by 27
Cooperativity of Rb, Brca1, and p53 in Malignant Breast Cancer Evolution
Kumar, P., Mukherjee, M., Johnson, J. P. S., Patel, M., Huey, B., Albertson, D. G., & Simin, K. J. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1003027 · Cited by 27
Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer
Jaeger, S. A., Min, J., Nigsch, F., Camargo, M. L., Hutz, J., Cornett, A., Cleaver, S. H., Buckler, A., & Jenkins, J. L. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114522690 · Cited by 27
Genomic Alteration During Metastasis of Lung Adenocarcinoma
Tan, Q., Cui, J., Huang, J. M., Ding, Z., Lin, H., Niu, X., Li, Z., Wang, G., Luo, Q., & Lu, S. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000438644 · Cited by 28
Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates Multiple Stages of B Cell Development
Lentucci, C., Belkina, A. C., Cederquist, C., Chan, M., Johnson, H. E., Prasad, S., Lopacinski, A., Nikolajczyk, B. S., Monti, S., Snyder-Cappione, J. E., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755132 · Cited by 27
Romagnoli, G., Wiedermann, M., Hübner, F., Wenners, A. S., Mathiak, M., Röcken, C., Maass, N., Klapper, W., & Alkatout, İ. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091936 · Cited by 27
A survey of Fusobacterium nucleatum genes modulated by host cell infection
Cochrane, K., Robinson, A. V., Holt, R. A., & Allen‐Vercoe, E. (2019) · Microbial Genomics · doi:10.1099/mgen.0.000300 · Cited by 28
Gene-Expression-Based Predictors for Breast Cancer
Gupta, A., Mutebi, M. C., & Bardia, A. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4703-0 · Cited by 28
Systems consequences of amplicon formation in human breast cancerPreprint
Inaki, K., Menghi, F., Woo, X. Y., Wagner, J. P., Jacques, P., Lee, Y. F., Shreckengast, P. T., Soon, W. W., Malhotra, A., Teo, A. S. M., et al. (2014) · Genome Research · doi:10.1101/gr.164871.113 · Cited by 26
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
López-Mejía, J. A., Mantilla-Ollarves, J. C., & Rocha‐Zavaleta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914777 · Cited by 26
Gu, T., Xiao, Y.-L., & Shao, Z.-M. (2024) · Precision Medicine and Engineering · doi:10.1016/j.preme.2024.100006 · Cited by 25
The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells
Balça-Silva, J., Matias, D., Dubois, L. G., Carneiro, B., do Carmo, A., Girão, H., Ferreira, F. L., Ferrer, V. P., Chimelli, L. M. C., Filho, P. N., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.04.005 · Cited by 26
Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer
Saleh, S. M. I., Bertos, N., Gruosso, T., Gigoux, M., Souleimanova, M., Zhao, H., Ömeroğlu, A., Hallett, M. T., & Park, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3427 · Cited by 25
BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
Patra, S., Young, V., Llewellyn, L., Senapati, J. N., & Mathew, J. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.8.2209 · Cited by 26
Precision medicine and bladder cancer heterogeneity
Ma, G., Yang, X., Liang, Y., Wang, L., Li, D., Chen, Y., Liang, Z., Wang, Y., & Niu, H. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.07.015 · Cited by 26
Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes
Elfgen, C., Reeve, K. A., Moskovszky, L. E., Güth, U., Bjelic‐Radisic, V., Fleisch, M. C., Tausch, C., & Varga, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02968-2 · Cited by 26
NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity
Haider, N., Dutt, P., van de Kooij, B., Ho, J., Palomero, L., Pujana, M. Á., Yaffe, M. B., & Stambolic, V. (2020) · Oncogene · doi:10.1038/s41388-020-1361-x · Cited by 26
Ferrucci, V., Asadzadeh, F., Collina, F., Siciliano, R., Boccia, A. S., Marrone, L., Spano, D., Carotenuto, M., Chiarolla, C. M., Martino, D. D., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101938 · Cited by 26
Xia, H., He, B., Wang, C., Zhang, H.-L., Ge, G., Zhang, Y.-X., Lv, L., Jiao, J., & Chen, C. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.012 · Cited by 26
Marouf, C., Göhler, S., Filho, M. I. D. S., Hajji, O., Hemminki, K., Nadifi, S., & Försti, A. (2016) · BMC Cancer · doi:10.1186/s12885-016-2210-8 · Cited by 27
Kono, M., Fujii, T., Matsuda, N., Harano, K., Chen, H., Wathoo, C., Joon, A. Y., Tripathy, D., Meric‐Bernstam, F., & Ueno, N. T. (2018) · Journal of Cancer · doi:10.7150/jca.26825 · Cited by 26
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
Saravia, C. H., Flores, C. J., Schwarz, L. J., Bravo, L., Zavaleta, J., Araujo, J. M., Neciosup, S. P., & Pinto, J. A. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554919868482 · Cited by 26
Walsh, E. M., Shalaby, A., O’Loughlin, M., Keane, N., Webber, M., Kerin, M. J., Keane, M., Glynn, S. A., & Callagy, G. M. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5066-6 · Cited by 26
Zaikova, E., Cheng, B. Y. C., Cerda, V., Kong, E., Lai, D., Lum, A. M., Bates, C., den Brok, W. D., Kono, T., Bourque, S., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-023-00607-1 · Cited by 25
Self-citationZacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 28
Bertrand, D., Drissler, S., Chia, B. K. H., Koh, J. Y., Li, C., Suphavilai, C., Tan, I. B., & Nagarajan, N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1345 · Cited by 25
Jokela, T. A., Engelsen, A. S. T., Rybicka, A. M., Vatter, F. A. P., Garbe, J. C., Miyano, M., Tiron, C. E., Ferariu, D., Akslen, L. A., Stampfer, M. R., et al. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00041 · Cited by 25
Howard, J., Wyse, C. A., Argyle, D. J., Quinn, C., Kelly, P., & McCann, A. H. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188431 · Cited by 25
Zhang, F., Wu, Z., Long, F., Tan, J., Gong, N., Li, X., & Lin, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.927682 · Cited by 29
Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
Cuenca-López, M. D., Serrano‐Heras, G., Montero, J. C., Corrales‐Sánchez, V., Sango, M. G., Gascón-Escribano, M. J., Morales, J. C., Voisin, V., Núñez, L. E., Morís, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4736 · Cited by 25
Tessari, A., Cosimo, S. D., & Palmieri, D. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53304 · Cited by 26
Collection, integration and analysis of cancer genomic profiles: from data to insight
Gao, J., Ciriello, G., Sander, C., & Schultz, N. D. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.003 · Cited by 25
Laurberg, J. R., Jensen, J. B., Schepeler, T., Borre, M., Orntoft, T. F., & Dyrskjøt, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-638 · Cited by 25
Jacot, W., Mollévi, C., Fina, F., Lopez‐Crapez, E., Martin, P., Colombo, P., Bibeau, F., Romieu, G., & Lamy, P. (2015) · BMC Cancer · doi:10.1186/s12885-015-1977-3 · Cited by 25
Exosomes: The Link between GPCR Activation and Metastatic Potential?
Isola, A. L., & Chen, S. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00056 · Cited by 25
The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring
Openshaw, M. R., Page, K., Fernández-García, D., Guttery, D. S., & Shaw, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1184974 · Cited by 27
Song, W., Tang, L., Xu, Y., Xu, J., Zhang, W., Xie, H., Wang, S., & Guan, X. (2017) · Scientific Reports · doi:10.1038/srep42319 · Cited by 25
Applications of RNA Indexes for Precision Oncology in Breast Cancer
Ma, L., Liang, Z., Zhou, H., & Qu, L. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.03.002 · Cited by 27
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era
Shee, K., Muller, K. E., Marotti, J. D., Miller, T. W., Wells, W. A., & Tsongalis, G. J. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.08.020 · Cited by 25
Lee, K., Chen, G., Chen, T., Kuo, Y., & Su, Y.-K. (2020) · Cancers · doi:10.3390/cancers12082122 · Cited by 25
Vaca‐Paniagua, F., Álvarez-Gómez, R. M., Maldonado-Martínez, H. A., Pérez‐Plasencia, C., Fragoso‐Ontiveros, V., Lasa-Gonsebatt, F., Herrera, L. A., de León, D. F. C., Bargalló‐Rocha, E., Mohar, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126762 · Cited by 25
Yuan, Y., Kos, F. J., He, T.-F., Yin, H. H., Li, M., Hardwick, N., Zurcher, K., Schmolze, D., Lee, P., Pillai, R. K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363138 · Cited by 23
Diversity of Intercellular Communication Modes: A Cancer Biology Perspective
Ebrahim, T., Ebrahim, A. S., & Kandouz, M. (2024) · Cells · doi:10.3390/cells13060495 · Cited by 25
Hansen, A. R., & Bedard, P. L. (2013) · Breast Cancer Research · doi:10.1186/bcr3558 · Cited by 24
Epistatic interactions and drug response
Weigelt, B., & Reis-Filho, J. S. (2013) · The Journal of Pathology · doi:10.1002/path.4265 · Cited by 26
Kim, H.-Y., Choi, H., Lee, J., & Kong, G. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz003 · Cited by 24
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
Lluch, A. M., Gonzalez-Angulo, A. M., Casadevall, D., Eterovic, A. K., de Dueñas, E. M., Zheng, X., Zotano, Á. G., Liu, S., Pérez, R. M., Chen, K., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.003 · Cited by 24
Peck, B., Bland, P. J., Mavrommati, I., Muirhead, G., Cottom, H., Wai, P. T., Maguire, S. L., Barker, H. E., Morrison, E., Kriplani, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1822 · Cited by 24
Asad, S., Barcenas, C. H., Bleicher, R. J., Cohen, A. L., Javid, S. H., Levine, E. G., Lin, N., Moy, B., Niland, J. C., Wolff, A. C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7659 · Cited by 24
Gawin, M., Kurczyk, A., Niemiec, J. A., Stanek‐Widera, A., Grela-Wojewoda, A., Adamczyk, A., Biskup-Frużyńska, M., Polańska, J., & Widłak, P. (2021) · Cancers · doi:10.3390/cancers13174349 · Cited by 24
Font-Clos, F., Zapperi, S., & Porta, C. A. M. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-13428-2 · Cited by 24
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory
Allegrucci, C., & Shah, M. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s26434 · Cited by 24
Lee, J., Galloway, R., Grandjean, G., Jacob, J., Humphries, J., Bartholomeusz, C., Goodstal, S. M., Lim, B., Bartholomeusz, G. A., Ueno, N. T., et al. (2015) · Journal of Cancer · doi:10.7150/jca.13266 · Cited by 24
Somatic gene mutation analysis of triple negative breast cancers
Dillon, J. L., Mockus, S. M., Ananda, G., Spotlow, V., Wells, W. A., Tsongalis, G. J., & Marotti, J. D. (2016) · The Breast · doi:10.1016/j.breast.2016.06.018 · Cited by 24
Zhang, J., Yan, S., Liu, X., Gan, L., Wu, Z., Gong, Y., Huang, M., Zhang, X., & Guo, W. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx046 · Cited by 23
Fabbri, F., Salvi, S., & Bravaccini, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.015 · Cited by 27
Smith, B. A., Shelton, D. N., Kieffer, C., Milash, B. A., Usary, J., Perou, C. M., Bernard, P. S., & Welm, B. E. (2012) · Genes & Cancer · doi:10.1177/1947601913475359 · Cited by 22
Pourteimoor, V., Mohammadi‐Yeganeh, S., & Paryan, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5349-7 · Cited by 24
The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer
Mallick, S., Duttaroy, A. K., & Dutta, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102140 · Cited by 23
Blau, C. A., Ramirez, A. B., Blau, S. H., Pritchard, C. C., Dorschner, M. O., Schmechel, S. C., Martins, T. J., Mahen, E. M., Burton, K. A., Komashko, V., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0003 · Cited by 24
Ueda, T., Nakata, Y., Yamasaki, N., Oda, H., Sentani, K., Kanai, A., Onishi, N., Ikeda, K., Sera, Y., Honda, Z.-I., et al. (2016) · Oncogene · doi:10.1038/onc.2015.519 · Cited by 23
Li, M., Zhang, J., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2016) · Gene · doi:10.1016/j.gene.2016.03.004 · Cited by 23
Expression pattern, regulation, and clinical significance of TOX in breast cancer
Arora, M., Kumari, S., Singh, J., Chopra, A., & Chauhan, S. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02689-3 · Cited by 24
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
Koh, S., Ross, K. N., Isakoff, S. J., Melkonjan, N., He, L., Matissek, K. J., Schultz, A., Mayer, E. L., Traina, T. A., Carey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0714 · Cited by 23
Eustace, A. J., Lee, M. J., Colley, G., Roban, J., Downing, T., & Buchanan, P. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.41 · Cited by 22
Yuan, L.-F., Liu, J.-N., Bao, L., Qu, H.-J., Xiang, J.-Y., & Sun, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1032364 · Cited by 23
Cancer networks and beyond: Interpreting mutations using the human interactome and protein structure
Gulati, S., Cheng, T. M. K., & Bates, P. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.002 · Cited by 23
Sapkota, Y., Ghosh, S., Lai, R. L., Coe, B. P., Cass, C. E., Yasui, Y., Mackey, J. R., & Damaraju, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053850 · Cited by 23
Self-citationIdentification of p53 and Its Isoforms in Human Breast Carcinoma Cells
Milićević, Z., Bajić, V., Živković, L., Kasapović, J., Andjelković, U., & Spremo‐Potparević, B. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/618698 · Cited by 26
Systematic investigation of cancer-associated somatic point mutations in SNP databases
Jung, H., Bleazard, T., Lee, J., & Hong, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2681 · Cited by 23
Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer
Fosu-Mensah, N., Peris, M. S., Weeks, H. P., Cai, J., & Westwell, A. D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.129 · Cited by 23
Developmental Insights into Breast Cancer Intratumoral Heterogeneity
Zhang, M., & Rosen, J. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.005 · Cited by 23
Encinas, G., Maistro, S., Pasini, F. S., Katayama, M. L. H., Brentani, M. M., de Bock, G. H., & Folgueira, M. A. A. K. (2015) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.61.05.474 · Cited by 23
Zhu, B., Mukherjee, A., Machiela, M. J., Song, L., Hua, X., Shi, J., García‐Closas, M., Chanock, S. J., & Chatterjee, N. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.223 · Cited by 23
Metadata
- Authors
- Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., Bashashati, A., Prentice, L. M., Khattra, J., Burleigh, A., Yap, D., Bernard, V., McPherson, A., Shumansky, K., Crisan, A., Giuliany, R., Heravi-Moussavi, A., Rosner, J., Lai, D., Birol, I., Varhol, R., Tam, A., Dhalla, N., Zeng, T., Ma, K., Chan, S. K., Griffith, M., Moradian, A., Cheng, S.-W. G., Morin, G. B., Watson, P., Gelmon, K., Chia, S., Chin, S.-F., Curtis, C., Rueda, O. M., Pharoah, P. D., Damaraju, S., Mackey, J., Hoon, K., Harkins, T., Tadigotla, V., Sigaroudinia, M., Gascard, P., Tlsty, T., Costello, J. F., Meyer, I. M., Eaves, C. J., Wasserman, W. W., Jones, S., Huntsman, D., Hirst, M., Caldas, C., Marra, M. A., & Aparicio, S.
- Affiliations
- University of British Columbia (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- University of Southern California (US)
- Cancer Research UK (GB)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Corresponding author
- Shah, Sohrab P.
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- ORCID
- Shah, Sohrab P.
- Roth, Andrew
- Ha, Gavin
- Zhao, Yongjun
- Turashvili, Gulisa
- Ding, Jiarui
- Haffari, Gholamreza
- Bashashati, Ali
- Prentice, Leah M.
- Burleigh, Angela
- Yap, Damian
- McPherson, Andrew
- Crisan, Anamaria
- Rosner, Jamie
- Lai, Daniel
- Varhol, Richard
- Tam, Angela
- Griffith, Malachi
- Moradian, Annie
- Cheng, S.-W. Grace
- Morin, Gregg B.
- Watson, Peter
- Gelmon, Karen
- Chia, Stephen
- Chin, Suet-Feung
- Curtis, Christina
- Rueda, Oscar M.
- Pharoah, Paul D.
- Damaraju, Sambasivarao
- Mackey, John
- Harkins, Timothy
- Gascard, Philippe
- Tlsty, Thea
- Costello, Joseph F.
- Meyer, Irmtraud M.
- Eaves, Connie J.
- Wasserman, Wyeth W.
- Jones, Steven
- Huntsman, David
- Hirst, Martin
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-04
- Volume
- 486
- Issue
- 7403
- Pages
- 395-399
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3863681
- OpenAlex
- W2063382533
- Cited by
- 1,967
- References
- 23
- Citations by year
- 2026: 40 · 2025: 61 · 2024: 71 · 2023: 131 · 2022: 132 · 2021: 119 · 2020: 131 · 2019: 120 · 2018: 135 · 2017: 173 · 2016: 179 · 2015: 198 · 2014: 199 · 2013: 201 · 2012: 76
- FWCI
- 71.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Canada's Michael Smith Genome Sciences Centre
- Canadian Breast Cancer Research Alliance
- Michael Smith Health Research BC
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0611-10154)
- Cure Brain Cancer Foundation
- BC Cancer Foundation
- National Institutes of Health
- Imperial Experimental Cancer Medicine Centre
- BC Cancer Agency
- National Institute of General Medical Sciences (R01GM084875)
- National Institute of Environmental Health Sciences (U01ES017154)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- triple-negative breast cancer, clonal evolution, somatic mutations, copy number variation, cancer genomics, TP53 mutation, PIK3CA mutation, PTEN mutation, basal subtype, tumor progression, founder mutation, clonal heterogeneity
- MeSH terms
- Alleles, Breast Neoplasms, Clone Cells, DNA Mutational Analysis, Female, Genotype, Humans, Mutation, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Analysis, RNA, Disease Progression, Evolution, Molecular, Gene Expression Profiling, INDEL Mutation, DNA Copy Number Variations, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
